TrialCancer chemotherapy and pharmacology2022

Cabozantinib with or without Panitumumab for RAS wild-type metastatic colorectal cancer: impact of MET amplification on clinical outcomes and circulating biomarkers.

Jingquan Jia et al.PubMed ↗Publisher ↗

No numbers read from the abstract.